Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Dr Martin Connor
m.connor@imperial.ac.uk


None . General clinical enquires
imperial.avidity@nhs.net


Prof Hashim U Ahmed
hashim.ahmed@imperial.ac.uk


Mr Samuel Morris
s.j.morris@imperial.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A clinical trial to find out if using the findings from PSMA PET scans to escalate treatment can improve cancer control in patients with high-risk prostate cancer
Back

A clinical trial to find out if using the findings from PSMA PET scans to escalate treatment can improve cancer control in patients with high-risk prostate cancer

Recruiting

Open to: Male

Age: Mixed

London

Medical Conditions

Prostate cancer

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The study is looking at whether we can improve outcomes for patients with newly-diagnosed high-risk prostate cancer

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

02 Feb 2026 06 Feb 2028

Patients will undergo three imaging tests (CT, bone scan and PSMA PET-CT). After they have completed all the imaging tests they will be randomly placed in 1 of 2 groups. The participant will have an equal chance of being in group 1 or group 2. If they are in Group 1, their care will follow standard NHS practice. Their clinical team will see the results of only the CT and bone scan and any normal treatment that is routinely given in the NHS will continue. If they are in Group 2, the clinical team will see only the PSMA PET-CT results. Their treatment will be directed by the PSMA PET-CT scan results. If the participant joins the study, they will not be able to see the results of all the imaging tests, even if they withdraw, until 51 months after signing the consent form. This is to ensure that the treatment in each group is only guided by the imaging tests that can be seen for that group. Otherwise, the results of the study will not be good enough to make any decisions on whether PSMA PET-CT should be used in future.


Adults over the age of 18 who have been newly diagnosed with high-risk prostate cancer

You can take part if:



You may not be able to take part if:


1. M1 on standard prostate MRI2. Unable to undergo prostate/pelvic MRI, CT-TAP, radio-isotope bone-scan, or PSMA PET-CT 3. Unable to receive iodinated contrast (eg contrast allergy, significant renal impairment) 4. Previous imaging, other than screening pelvic MRI, for the primary purpose of staging pelvic nodal or distant metastatic disease of prostate cancer within 8 weeks prior to randomisation5. Previous local or systemic (including any ADT/ARTA/docetaxel chemotherapy) treatment of prostate cancer (5-alpha reductase inhibitors are permitted)6. Other malignancies diagnosed in previous 2 years (except non-melanoma skin cancer)7. Variant/non-adenocarcinoma histology (e.g., spindle cell, neuroendocrine)8. Already commenced hormone treatment


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Charing Cross Hospital
    Department of Urology Fulham Palace Road
    London
    W6 8RF

There may not be any personal benefits for the participant, however patients who are randomised to have the PSMA PET-CT might have metastases detected earlier, but we do not know if the change in the treatment that this might lead to will change cancer control. This study is needed because we are not sure which approach is better. We cannot promise the study will help the participant directly, but the information we get might help improve the treatment of patients with prostate cancer in the future.
If a patient take part in this study they will have PSMA PET-CT scans, CT scans and bone scans. Some of these will be extra to those that the participant would have if they did not take part. These procedures use ionising radiation to form images of their body to provide their doctor with clinical information. Ionising radiation may cause cancer many years or decades after the exposure. The chances of this happening to the participant as a consequence of taking part in this study are about 0.6%. These scans also require an injection into the participant vein. This can sometimes lead to mild bruising of the skin.
As with any tests for cancer there can be false negatives and false positives. No medical test is completely accurate. We have evidence that PSMA PET-CT detects more metastases than CT and bone scans. However, they may not pick up all metastases. At the same time, the tests can sometimes be positive in patients who do not have metastases. These patients will be offered a different set of treatments based on this scan result.

Prof Hashim U Ahmed
hashim.ahmed@imperial.ac.uk


Mr Samuel Morris
s.j.morris@imperial.ac.uk


None . General clinical enquires
imperial.avidity@nhs.net


Dr Martin Connor
m.connor@imperial.ac.uk



The study is sponsored by Imperial College London and funded by Prostate Cancer UK.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN78360465

Or CPMS: 72253

Last updated 28 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top